Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer
Abstract Background Gastric cancer (CC) is a disease with high incidence and mortality rate. Immunotherapy is an important method for gastric cancer while lack of effective predictor. Integrins play an important role in the development. We aimed to explore the predictive value of β1 integrin (ITGB1)...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-09-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-023-02930-0 |
| _version_ | 1827634141382836224 |
|---|---|
| author | Chao Xu Xiao-Li Xie Ning Kang Hui-Qing Jiang |
| author_facet | Chao Xu Xiao-Li Xie Ning Kang Hui-Qing Jiang |
| author_sort | Chao Xu |
| collection | DOAJ |
| description | Abstract Background Gastric cancer (CC) is a disease with high incidence and mortality rate. Immunotherapy is an important method for gastric cancer while lack of effective predictor. Integrins play an important role in the development. We aimed to explore the predictive value of β1 integrin (ITGB1) as a predictor of immunnotherapy in gastric cancer. Methods Differential expression analysis was conducted using the Gene Expression Profiling Interactive Analysis (GEPIA) 2.0 and GEO databases. GEPIA data were used to evaluate the prognostic value of ITGB1 in gastric cancer (GC). Transcriptomic and clinical data of GC and normal tissues were downloaded from The Cancer Genome Atlas database, and the TIMER database was used to evaluate the association between ITGB1 and immune infiltration. Time-dependent receiver operating characteristic (ROC) curve analysis was used to determine the prognostic value of ITGB1. To verify ITGB1 expression at the protein level, immunohistochemical staining was conducted. In addition, to analyze the correlation of ITGB1 with PD-1 and PD-L1, we examined levels of PD-1 and PD-L1 by IHC and determined the predictive value of ITGB1 for anti-PD-1 therapy in GC by ROC curve analysis. Results Compared with normal tissues, analysis of GEPIA and data at protein levels showed significantly higher expression of ITGB1 in GC. In addition, higher expression of ITGB1 was associated with worse pathological G-staging and tumor T-staging, which suggested that ITGB1 is a risk factor for poor prognosis in GC. The level of ITGB1 expression was positively correlated with CD8 + T cells, neutrophils, macrophages, and dendritic cells. ITGB1 expression was also correlated with PD-L1 expression, and this was further verified at the protein level by immunohistochemical analysis. The area under the ROC curve was 0.808. Conclusion ITGB1 may be a promising prognostic biomarker and effective predictor for anti-PD-1 therapy in GC. Trial registration Retrospectively registered. |
| first_indexed | 2024-03-09T15:09:15Z |
| format | Article |
| id | doaj.art-d556b4a9ef5f4e9492e067aea36c05f1 |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-03-09T15:09:15Z |
| publishDate | 2023-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-d556b4a9ef5f4e9492e067aea36c05f12023-11-26T13:30:27ZengBMCBMC Gastroenterology1471-230X2023-09-0123111610.1186/s12876-023-02930-0Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancerChao Xu0Xiao-Li Xie1Ning Kang2Hui-Qing Jiang3Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Hebei Clinical Research Center for Digestive DiseasesDepartment of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Hebei Clinical Research Center for Digestive DiseasesDepartment of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Hebei Clinical Research Center for Digestive DiseasesDepartment of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Hebei Clinical Research Center for Digestive DiseasesAbstract Background Gastric cancer (CC) is a disease with high incidence and mortality rate. Immunotherapy is an important method for gastric cancer while lack of effective predictor. Integrins play an important role in the development. We aimed to explore the predictive value of β1 integrin (ITGB1) as a predictor of immunnotherapy in gastric cancer. Methods Differential expression analysis was conducted using the Gene Expression Profiling Interactive Analysis (GEPIA) 2.0 and GEO databases. GEPIA data were used to evaluate the prognostic value of ITGB1 in gastric cancer (GC). Transcriptomic and clinical data of GC and normal tissues were downloaded from The Cancer Genome Atlas database, and the TIMER database was used to evaluate the association between ITGB1 and immune infiltration. Time-dependent receiver operating characteristic (ROC) curve analysis was used to determine the prognostic value of ITGB1. To verify ITGB1 expression at the protein level, immunohistochemical staining was conducted. In addition, to analyze the correlation of ITGB1 with PD-1 and PD-L1, we examined levels of PD-1 and PD-L1 by IHC and determined the predictive value of ITGB1 for anti-PD-1 therapy in GC by ROC curve analysis. Results Compared with normal tissues, analysis of GEPIA and data at protein levels showed significantly higher expression of ITGB1 in GC. In addition, higher expression of ITGB1 was associated with worse pathological G-staging and tumor T-staging, which suggested that ITGB1 is a risk factor for poor prognosis in GC. The level of ITGB1 expression was positively correlated with CD8 + T cells, neutrophils, macrophages, and dendritic cells. ITGB1 expression was also correlated with PD-L1 expression, and this was further verified at the protein level by immunohistochemical analysis. The area under the ROC curve was 0.808. Conclusion ITGB1 may be a promising prognostic biomarker and effective predictor for anti-PD-1 therapy in GC. Trial registration Retrospectively registered.https://doi.org/10.1186/s12876-023-02930-0ITGB1Gastric cancerBio-informaticsPredictive valueImmunohistochemistryImmunotherapy |
| spellingShingle | Chao Xu Xiao-Li Xie Ning Kang Hui-Qing Jiang Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer BMC Gastroenterology ITGB1 Gastric cancer Bio-informatics Predictive value Immunohistochemistry Immunotherapy |
| title | Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer |
| title_full | Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer |
| title_fullStr | Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer |
| title_full_unstemmed | Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer |
| title_short | Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer |
| title_sort | evaluation of itgb1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer |
| topic | ITGB1 Gastric cancer Bio-informatics Predictive value Immunohistochemistry Immunotherapy |
| url | https://doi.org/10.1186/s12876-023-02930-0 |
| work_keys_str_mv | AT chaoxu evaluationofitgb1expressionasapredictorofthetherapeuticeffectsofimmunecheckpointinhibitorsingastriccancer AT xiaolixie evaluationofitgb1expressionasapredictorofthetherapeuticeffectsofimmunecheckpointinhibitorsingastriccancer AT ningkang evaluationofitgb1expressionasapredictorofthetherapeuticeffectsofimmunecheckpointinhibitorsingastriccancer AT huiqingjiang evaluationofitgb1expressionasapredictorofthetherapeuticeffectsofimmunecheckpointinhibitorsingastriccancer |